Prakt. lékáren. 2005; 1(1): 18

Končí dostupnost pindololu

PharmDr. Kamil Hrubý Ph.D
_

Pindolol (APO-Pindol®) přestal být v České republice dostupný z důvodu rozhodnutí výrobce o ukončení dovozu (1). Přípravek se v současnosti doprodává. Originální přípravek Visken® není u nás dostupný už dlouhou dobu. Molekula pindololu (obrázek 1) byla patentována v roce 1969 společností Sandoz (2).

Published: February 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hrubý K. Končí dostupnost pindololu. Praktické lékárenství. 2005;1(1):18.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Informační dopis společnosti Apotex.
    2. Pindolol. In: The Merck Index1996. Merck & Co., Inc. 1996: 1280.
    3. Beta-adrenergic blocking agents. In: Drug Facts and Comparisons. Facts and Comparisons 2001: 477.
    4. Pindolol, souhrn SPC. Mikro-verze AISLP - ČR 2005: 2.
    5. Pindolol. In: Martindale, The complete drug reference. Pharmaceutical Press 1999: 931.
    6. Hunter Hypertension Research Group. Effects of pindolol, or a pindolol/clopamide combination preparation, on plasma lipid levels in essential hypertension. Med J Aust 1989; 150: 646-652. Go to original source... Go to PubMed...
    7. Terént A, et al. Long-term effects of pindolol on lipids and pipoproteins in men with newly diagnosed hypertension. Eur J Clin Pharmacol 1989; 36: 347-350. Go to original source... Go to PubMed...
    8. Rabiner ER, et al. Preferential 5-HT1A autoreceptor occupancy by pindolol is attenuated in depressed patients: effect of treatment or an endophenotype of depression? Neuropsychopharmacology 2004; 29: 1688-1698. Go to original source... Go to PubMed...
    9. Thase ME. Therapeutic alternatives for difficult-to-treat depression: a narrative review of the state of the evidence. CNS Spectr 2004; 9: 818-821. Go to original source... Go to PubMed...
    10. Ballesteros J, Callado LF. Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials. J Affect Disord 2004; 79: 137-147. Go to original source... Go to PubMed...
    11. Isaac MT, et al. Milnacipran and pindolol: a randomized trial of reduction of antidepressant latency. Hum Psychopharmacol 2003; 18: 595-601. Go to original source... Go to PubMed...
    12. Caspi N, et al. Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study. Int Clin Psychopharmacol 2001; 16: 111-115. Go to original source... Go to PubMed...
    13. Hirschmann S, et al. Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial. J Clin Psychopharmacol 2000; 20: 556-559. Go to original source... Go to PubMed...
    14. Electronic Orange Book. www.fda.gov.
    15. www.rote-liste.de/Online.
    16. www.bnf.org.

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.